论文部分内容阅读
目的分析检测CA125、CA19-9在卵巢癌诊治中的应用价值。方法对76例卵巢肿瘤分为卵巢癌组和卵巢良性肿瘤组,应用化学发光法检测CA125、CA19-9并分析。结果观察组36例,CA125阳性28例,测得均值为345.3 U/ml,阳性率为77.8%;CA19-9阳性19例,测得均值为69.6 U/ml,阳性率52.8%;联合检测阳性32例,阳性率为88.9%;对照组40例,CA125阳性3例(畸胎瘤患者),测得均值为40.6 U/ml,阳性率为7.5%;CA19-9阳性0例,测得均值为26.4 U/ml;联合检测阳性3例,阳性率为7.5%,两组比较差异具有统计学意义(P<0.05)。结论联合检测CA125、CA19-9可提高卵巢癌的阳性率。
Objective To analyze the value of detecting CA125 and CA19-9 in the diagnosis and treatment of ovarian cancer. Methods 76 cases of ovarian tumors were divided into ovarian cancer group and benign ovarian tumor group. Chemiluminescence method was used to detect CA125 and CA19-9. Results The observation group consisted of 36 cases with CA125 positive in 28 cases. The mean value was 345.3 U / ml, the positive rate was 77.8%. In CA19-9 positive group, the mean was 69.6 U / ml and the positive rate was 52.8% 32 cases, the positive rate was 88.9%; 40 cases of control group, CA125-positive in 3 cases (teratoma patients), the mean was 40.6 U / ml, the positive rate was 7.5%; CA19-9 positive in 0 cases, the mean (26.4 U / ml). The positive rate of the combined test was 3% (positive rate was 7.5%). There was significant difference between the two groups (P <0.05). Conclusion Combined detection of CA125 and CA19-9 can improve the positive rate of ovarian cancer.